New data analysis shows benefit of Lexicon’s sotagliflozin

USA-based Lexicon Pharmaceuticals (Nasdaq: LXRX) yesterday announced that a post-hoc analysis of Phase III data from the SCORED clinical trial demonstrated that Inpefa (sotagliflozin) reduced the risk of major adverse cardiovascular events (MACE) and heart failure (HF) events across the spectrum of diabetes duration.

US Food and Drug Administration (FDA) approved Inpefa last year to reduce the risk of cardiovascular death, hospitalization for heart failure.

Researchers noted that HF patients with longer durations of diabetes derived greater benefit from INPEFA, even controlling for similar baseline HbA1c, yet all patients regardless of diabetes duration benefited from the therapy. These findings were presented at the European Society of Cardiology (ESC) Congress 2024 in London, UK.